DK2073842T3 - Anvendelse af humane celler af myeloid leukæmioprindelse til ekspression af antistoffer. - Google Patents

Anvendelse af humane celler af myeloid leukæmioprindelse til ekspression af antistoffer. Download PDF

Info

Publication number
DK2073842T3
DK2073842T3 DK07818090T DK07818090T DK2073842T3 DK 2073842 T3 DK2073842 T3 DK 2073842T3 DK 07818090 T DK07818090 T DK 07818090T DK 07818090 T DK07818090 T DK 07818090T DK 2073842 T3 DK2073842 T3 DK 2073842T3
Authority
DK
Denmark
Prior art keywords
antibodies
expression
human cells
myeloid leukemia
leukemia origin
Prior art date
Application number
DK07818090T
Other languages
English (en)
Other versions
DK2073842T4 (da
Inventor
Steffen Goletz
Antje Danielczyk
Hans Baumeister
Renate Stahn
Anja LÖFFLER
Lars Stöckl
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39157600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2073842(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06090171A external-priority patent/EP1900750A1/en
Priority claimed from EP06090190A external-priority patent/EP1911766A1/en
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of DK2073842T3 publication Critical patent/DK2073842T3/da
Application granted granted Critical
Publication of DK2073842T4 publication Critical patent/DK2073842T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK07818090.8T 2006-09-10 2007-09-10 Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer DK2073842T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06090162 2006-09-10
EP06090171A EP1900750A1 (en) 2006-09-18 2006-09-18 Fully human high yield production system for improved antibodies
EP06090190A EP1911766A1 (en) 2006-10-13 2006-10-13 Use of human cells of myeloid leukaemia origin for expression of antibodies
EP07090094 2007-05-04
PCT/EP2007/007877 WO2008028686A2 (en) 2006-09-10 2007-09-10 Use of human cells of myeloid leukaemia origin for expression of antibodies

Publications (2)

Publication Number Publication Date
DK2073842T3 true DK2073842T3 (da) 2015-04-13
DK2073842T4 DK2073842T4 (da) 2024-01-15

Family

ID=39157600

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07818090.8T DK2073842T4 (da) 2006-09-10 2007-09-10 Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer
DK11176197.9T DK2428224T3 (da) 2006-09-10 2007-09-10 Anvendelse af humane celler, der stammer fra myeloid leukæmi til at udtrykke antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11176197.9T DK2428224T3 (da) 2006-09-10 2007-09-10 Anvendelse af humane celler, der stammer fra myeloid leukæmi til at udtrykke antistoffer

Country Status (25)

Country Link
US (3) US9051356B2 (da)
EP (5) EP2428224B1 (da)
JP (3) JP5767779B2 (da)
KR (3) KR20150126730A (da)
CN (1) CN103436574B (da)
AU (1) AU2007294122B2 (da)
BR (1) BRPI0716997B8 (da)
CA (1) CA2662226C (da)
CU (1) CU23791A3 (da)
CY (1) CY1116279T1 (da)
DK (2) DK2073842T4 (da)
EA (1) EA017622B1 (da)
ES (2) ES2533964T5 (da)
FI (1) FI2073842T4 (da)
HR (1) HRP20150307T1 (da)
IL (1) IL197459A (da)
MX (1) MX2009002388A (da)
NZ (1) NZ575974A (da)
PL (1) PL2073842T3 (da)
PT (1) PT2073842E (da)
RS (1) RS53861B1 (da)
SG (1) SG174792A1 (da)
SI (1) SI2073842T1 (da)
WO (1) WO2008028686A2 (da)
ZA (1) ZA201001903B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528611B2 (ja) * 1998-07-16 2004-05-17 Ｊｆｅスチール株式会社 結束材の切断方法及びその装置
EP2428224B1 (en) 2006-09-10 2016-12-21 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008135259A2 (en) * 2007-05-04 2008-11-13 Glycotope Gmbh Antibody molecule composition
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
MX2011007545A (es) † 2009-01-22 2011-10-28 Momenta Pharmaceuticals Inc N-glicanos que contienen galactosa-alfa-1,3-galactosa en productos de glicoproteina derivados de celulas de ovario de hamster chino (cho).
WO2011003615A2 (en) 2009-07-08 2011-01-13 Glycotope Gmbh Perfusion bioreactor
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2603528B1 (en) * 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
ES2624479T3 (es) 2010-12-21 2017-07-14 Glycotope Gmbh Métodos para cultivar células de leucemia mieloide humana y células derivadas de esta
KR20140122649A (ko) 2011-04-21 2014-10-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (ADCs) 및 그의 용도
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2844435A1 (en) * 2011-08-10 2013-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated antibodies
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
CA2875486A1 (en) * 2012-07-18 2014-01-23 Glycotope Gmbh Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JP2016504047A (ja) 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
MX2015010428A (es) * 2013-02-13 2016-04-13 Lab Francais Du Fractionnement Anticuerpos anti-her2 altamente galactosilados y sus usos.
BR112015019339A2 (pt) * 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico
AR094778A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteínas con glicosilación modificada y métodos para producirlas
WO2014125374A2 (en) * 2013-02-13 2014-08-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
CA2906407A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN113549148A (zh) 2013-03-14 2021-10-26 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP2970865B1 (en) 2013-03-15 2020-09-02 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
EP2989126A1 (en) 2013-04-22 2016-03-02 Glycotope GmbH Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
KR102150481B1 (ko) * 2014-03-05 2020-09-02 울트라제닉스 파마수티컬 인코포레이티드 시알화 당단백질 조성물 및 이의 용도
US20150307546A1 (en) * 2014-04-29 2015-10-29 Georgia Tech Research Corporation Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
LU92659B1 (en) 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
RU2716974C2 (ru) 2015-03-31 2020-03-17 Гликотоп Гмбх Эукариотические экспрессионные векторы, содержащие регуляторные элементы кластеров гена глобина
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
BR112017027813A2 (pt) 2015-06-22 2018-08-28 Bayer Pharma Aktiengesellschaft conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis
MX2017017138A (es) 2015-06-23 2018-04-30 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2016207328A1 (en) 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20170114127A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
WO2017162663A1 (de) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
CN109310781A (zh) 2016-06-15 2019-02-05 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
US11713458B2 (en) 2016-06-20 2023-08-01 Octapharma Ag Means and methods for modifying multiple alleles
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
CA3050039A1 (en) 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP6829357B2 (ja) * 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
CA3055433A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
EP3601357A1 (en) 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
AU2018241916A1 (en) * 2017-03-29 2019-10-17 Glycotope Gmbh PD-L1 and TA-MUC1 antibodies
KR20200044118A (ko) 2017-09-06 2020-04-28 에어웨이 테라퓨틱스, 아이엔씨. 계면활성제 단백질 d (sp-d)를 제조하는 방법, 조성물 및 세포
BR112020004540A2 (pt) * 2017-09-06 2020-09-08 Airway Therapeutics, LLC métodos e composições para preparar proteína surfactante d (sp-d)
CN111819203A (zh) * 2018-03-01 2020-10-23 葛莱高托普有限公司 包含抗muc1抗体和il-15的融合蛋白构建体
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat
AU2020397803C1 (en) 2019-12-06 2023-05-11 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
EP4171749A1 (en) 2020-06-30 2023-05-03 Glycotope GmbH Humanized antibodies against lewis y
WO2023175117A1 (en) 2022-03-16 2023-09-21 Glycotope Gmbh Antibodies against lypd3

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
AU683413B2 (en) * 1992-04-13 1997-11-13 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
WO1995010538A1 (en) * 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
CA2309766C (en) * 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
WO2000052135A2 (en) 1999-03-02 2000-09-08 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
AU754808B2 (en) * 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001012217A1 (en) 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use
US6984384B1 (en) * 1999-09-30 2006-01-10 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (fr) 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
KR100866199B1 (ko) 2001-02-01 2008-10-30 가부시끼가이샤 야구르트혼샤 발효유 음식품 중의 비피도박테리움속 세균의 장내 도달도평가방법
US20050042714A1 (en) 2001-08-17 2005-02-24 Michael Pawlita Glycoconjugates of sialic acid derivates, methods for their production and use thereof
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
WO2003044051A1 (en) 2001-11-20 2003-05-30 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SI1529060T1 (sl) * 2002-07-22 2015-01-30 Glycotope Gmbh Postopek za proizvodnjo imunostimulacijskih mucinov (MUCI)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
EP1789027B1 (en) 2004-07-26 2013-09-04 The Research Foundation Of State University Of New York Therapeutic use of anti-tf-antigen antibody
US20090046556A1 (en) 2006-02-14 2009-02-19 Koninklijke Philips Electronics N.V. Bit detection for optical disc reading
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
EP1911766A1 (en) 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1900750A1 (en) 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
EP2428224B1 (en) 2006-09-10 2016-12-21 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
AU2009248410B2 (en) 2008-05-13 2014-07-24 Glycotope Gmbh Fermentation process
JP5746018B2 (ja) 2009-04-16 2015-07-08 国立大学法人 東京大学 抗ｔｍｐｒｓｓ１１ｅ抗体を用いた癌の診断と治療
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
JP2016504047A (ja) 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
JP2015138634A (ja) 2014-01-22 2015-07-30 株式会社オートネットワーク技術研究所 端子金具付き電線及びその製造方法

Also Published As

Publication number Publication date
DK2428224T3 (da) 2017-03-27
CN103436574A (zh) 2013-12-11
SG174792A1 (en) 2011-10-28
WO2008028686A2 (en) 2008-03-13
KR20170021375A (ko) 2017-02-27
JP5767779B2 (ja) 2015-08-19
RS53861B1 (en) 2015-08-31
EP2073842A2 (en) 2009-07-01
KR20150126730A (ko) 2015-11-12
WO2008028686A3 (en) 2008-06-12
CY1116279T1 (el) 2017-02-08
EP2428224A3 (en) 2012-05-09
EP2428224B1 (en) 2016-12-21
US20190359731A1 (en) 2019-11-28
DK2073842T4 (da) 2024-01-15
IL197459A0 (en) 2011-08-01
EP2428223A3 (en) 2012-05-16
ES2533964T3 (es) 2015-04-16
AU2007294122A1 (en) 2008-03-13
MX2009002388A (es) 2009-06-02
US20150368363A1 (en) 2015-12-24
CA2662226C (en) 2020-08-04
JP2017123879A (ja) 2017-07-20
PL2073842T3 (pl) 2015-06-30
AU2007294122B2 (en) 2013-03-07
BRPI0716997A8 (pt) 2019-02-05
CU23791A3 (es) 2012-03-15
IL197459A (en) 2015-08-31
KR101603632B1 (ko) 2016-03-16
US10280230B2 (en) 2019-05-07
EP2428224A2 (en) 2012-03-14
EP2428223A2 (en) 2012-03-14
ES2533964T5 (es) 2024-05-09
EP2073842B2 (en) 2023-10-18
SI2073842T1 (sl) 2015-05-29
EP2073842B1 (en) 2014-12-31
EP2428225A3 (en) 2012-05-09
CA2662226A1 (en) 2008-03-13
ZA201001903B (en) 2010-11-24
BRPI0716997B8 (pt) 2021-05-25
HRP20150307T1 (hr) 2015-04-24
US9051356B2 (en) 2015-06-09
JP2015146819A (ja) 2015-08-20
NZ575974A (en) 2012-03-30
JP2010502204A (ja) 2010-01-28
KR20090077911A (ko) 2009-07-16
ES2620261T3 (es) 2017-06-28
EA200970263A1 (ru) 2009-08-28
CN103436574B (zh) 2016-08-10
US20100028947A1 (en) 2010-02-04
EA017622B1 (ru) 2013-01-30
PT2073842E (pt) 2015-04-07
JP6166303B2 (ja) 2017-07-19
EP3539981A1 (en) 2019-09-18
FI2073842T4 (fi) 2024-01-15
BRPI0716997B1 (pt) 2020-06-02
BRPI0716997A2 (pt) 2013-10-15
EP2428225A2 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
DK2073842T3 (da) Anvendelse af humane celler af myeloid leukæmioprindelse til ekspression af antistoffer.
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
LTC2170959I2 (lt) Antikūnai prieš žmogaus užprogramuotą mirties receptorių PD-1
CR20130418A (es) Anticuerpos contra la angiopoyetina 2 humana (divisional exp. 2011-0321)
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2139390T3 (da) Fremgangsmåde til evaluering af effektiviteten af kommerciel kommunikation
BRPI0815983A2 (pt) anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
DK2066695T3 (da) Anti-myostatin-antistoffer
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
DK2131860T3 (da) Anti-sclerostin-antistoffer
DK2185693T3 (da) Differentiering af humane embryoniske stamceller
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0820407A2 (pt) Uso de anticorpos anti-cd40
ATE499453T1 (de) Zugerichtetes leder
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
DK3219328T3 (da) Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
CU23872B1 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
DK2043559T3 (da) System til anvendelse af ballonudvidelig hjerteklap
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2077287T3 (da) Fremgangsmåde til fremstilling af blødt polyurethanskum
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.